Pharmacologic management of patients with RA includes disease-modifying antirheumatic drugs (DMARDs), anti-tumor necrosis factor-alpha inhibitors, such as infliximab, etanercept, and adalimumab, and non-tumor necrosis factor inhibitors such as abatacept, rituximab, and tocilizumab [4]. This evidence concerns the gene TNF and rheumatoid arthritis.